Gibson Amy E, Degenhardt Louisa J
National Drug and Alcohol Research Centre, University of New South Wales, Australia.
Drug Alcohol Rev. 2007 Jul;26(4):405-10. doi: 10.1080/09595230701373834.
The aim of this study was to compare the mortality associated with oral naltrexone, methadone and buprenorphine in opioid dependence treatment, employing a retrospective data analysis using coronial and prescription data.
The number of deaths were identified through national coronial data and number of treatment recipients were estimated from 2000 to 2003 prescriptions and restricted medications data. Mortality rates were expressed as deaths per number of treatment episodes and per person-years at high and low risk of fatal opioid overdose.
Thirty-two oral naltrexone, one buprenorphine and 282 methadone-related deaths were identified. Mortality rates in the highest risk period in deaths per 100 person-years were 22.1 (14.6 - 32.2) for oral naltrexone following treatment cessation and 3.0 (2.3 - 3.9) for methadone during treatment induction. Rates in the lowest risk period in deaths per 100 person-years were 1.0 (0.3 - 2.2) during oral naltrexone treatment and 0.34 (0.3 - 0.4) during post-induction methadone treatment. The relative risk of death for oral naltrexone subjects was 7.4 times (high-risk period, p < 0.0001) or 2.8 times (low-risk period, p = 0.055) that of methadone subjects.
This is the first comparison of mortality associated with these three pharmacotherapies for opioid dependence. The risk of death related to oral naltrexone appears higher than that related to methadone treatment.
本研究旨在通过使用死因裁判和处方数据进行回顾性数据分析,比较阿片类药物依赖治疗中口服纳曲酮、美沙酮和丁丙诺啡相关的死亡率。
通过国家死因裁判数据确定死亡人数,并根据2000年至2003年的处方和受限药物数据估算治疗接受者人数。死亡率以每治疗疗程的死亡人数以及每100人年中阿片类药物致命过量高风险和低风险时的死亡人数表示。
确定了32例口服纳曲酮相关死亡、1例丁丙诺啡相关死亡和282例美沙酮相关死亡。每100人年中,口服纳曲酮停药后最高风险期的死亡率为22.1(14.6 - 32.2),美沙酮诱导治疗期间为3.0(2.3 - 3.9)。每100人年中,口服纳曲酮治疗期间最低风险期的死亡率为1.0(0.3 - 2.2),美沙酮诱导治疗后为0.34(0.3 - 0.4)。口服纳曲酮治疗对象的相对死亡风险是美沙酮治疗对象的7.4倍(高风险期,p < 0.0001)或2.8倍(低风险期,p = 0.055)。
这是首次对这三种阿片类药物依赖药物治疗相关死亡率进行比较。口服纳曲酮相关的死亡风险似乎高于美沙酮治疗相关的死亡风险。